BCTX Stock Summary and Trading Ideas (Briacell Therapeutics Corp. - Common Shares | NASDAQ:BCTX)

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Briacell Therapeutics Corp. - Common Shares trades on the NASDAQ stock market under the symbol BCTX.

As of June 26, 2026, BCTX stock price climbed to $3.06 with 96,075 million shares trading.

BCTX has a beta of 2.38, meaning it tends to be more sensitive to market movements. BCTX has a correlation of 0.05 to the broad based SPY ETF.

BCTX has a market cap of $26.62 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, BCTX traded as high as $1,138.49 and as low as $2.60.

BCTX has underperformed the market in the last year with a return of -89.6%, while the SPY ETF gained +21.3%. In the last 3 month period, BCTX fell short of the market, returning -24.4%, while SPY returned +11.3%. However, in the most recent 2 weeks BCTX has outperformed the stock market by returning +11.7%, while SPY returned -0.9%.

BCTX support price is $2.82 and resistance is $3.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCTX shares will trade within this expected range on the day.